Literature DB >> 24088763

Long-term remission achieved via combined chemotherapy and radiotherapy in a non-resectable granulocyte colony-stimulating factor producing pleomorphic carcinoma of the lung.

Masaki Yamamoto1, Saki Manabe, Yusuke Moriyama, Hiroshi Ishii, Shintetsu Tanaka, Ryohei Takahashi, Koji Tomaru, Nobuaki Kobayashi, Makoto Kudo, Masahiro Sasaki, Yoshiaki Inayama, Takeshi Kaneko, Yoshiaki Ishigatsubo.   

Abstract

The prognosis is poor for patients with advanced pleomorphic carcinoma of the lung due to the generally limited response to chemotherapy and/or radiotherapy. It has been suggested the production of granulocyte colony-stimulating factor (G-CSF) by cancer cells may aggravate the disease progression. We herein report a case of a 73-year-old Japanese man with advanced G-CSF-producing pleomorphic carcinoma of the lung. First-line chemotherapy with carboplatin and paclitaxel had been suspended. Subsequent radiotherapy achieved a moderate volume reduction and an amelioration of the excessive G-CSF-related complications. Six cycles of second-line chemotherapy with docetaxel administered with good results. These combined treatments resulted in long term survival without progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 24088763     DOI: 10.2169/internalmedicine.52.0701

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Granulocyte colony stimulating factor-producing lung cancer with severe anemia of inflammation.

Authors:  Koutaro Murakami; Yujin Kudo; Masatoshi Kakihana; Jun Matsubayashi; Tetsuya Okano; Yoshihisa Shimada; Toshitaka Nagao; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-28

2.  Pemetrexed and bevacizumab-containing chemotherapy for pleomorphic carcinoma of the lung.

Authors:  Tomohiro Tamura; Gen Ohara; Katsunori Kagohashi; Mio Kawaguchi; Koichi Kurishima; Hiroaki Satoh
Journal:  Mol Clin Oncol       Date:  2016-01-29

3.  Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.

Authors:  Takafumi Yorozuya; Tetsuya Taya; Kento Yasuda; Yutaro Nagano; Makoto Shioya; Hirofumi Chiba; Hiroki Takahashi
Journal:  Thorac Cancer       Date:  2020-02-11       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.